NeoPrediX USA, Inc. (US)

Fort Lauderdale,  FL 
United States
  • Booth: 338

Determining jaundice risk during an infant’s first hours of life is crucial since most
newborns are discharged before bilirubin levels peak. Current care standards lack
automation and are unable to properly forecast individual bilirubin progression.
The NeoPrediX B.1 solution uses a proprietary algorithm to predict the risk of jaundice
up to 60 hours in advance, and is backed by population data and a multi-site clinical trial.

For Technical Support with this webpage, please contact support.